Also, the comparative effectiveness of GLP1 receptor agonists and SGLT2 inhibitors has been a growing interest, and several cohort studies with robust methodology have concluded comparable dementia risk between initiators of GLP1 receptor agonists and SGLT2 inhibitors [16, 25, 26]. This evidence concerns the gene SLC5A2 and dementia.